阿托伐他汀钙强化降脂治疗动脉粥样硬化脑梗死患者的疗效及颈动脉斑块的影响分析
|
摘要
目的对阿托伐他汀钙强化降脂治疗动脉粥样硬化脑梗死患者的疗效以及颈动脉斑块的影响进行探讨。方法选择35例动脉粥样硬化脑梗死患者参与研究,临床上予以阿托伐他汀钙强化降脂治疗,并设为观察组。在相同的时间段抽取另外35例动脉粥样硬化脑梗死患者参与研究,临床上予以常规治疗,设为参照组。就两组患者的临床治疗情况以及预后情况展开分析和数据对比。结果观察组在治疗总有效率方面相对参照组更为出色,数值更高,与参照组相比差异显著且P<0.05,具有统计学意义;观察组在血脂方面相对参照组更为出色,数值方面各项指标水平改善幅度更大,与参照组差异较大,P<0.05,存在统计学意义;观察组在动脉粥样硬化方面相对参照组更为出色,数值方面颈动脉斑块面积、颈内膜-中层厚度改善幅度更大,与参照组相比差异显著且P<0.05,具有统计学意义。结论选择阿托伐他汀钙强化降脂治疗方案对动脉粥样硬化脑梗死患者进行临床干预,可对患者血脂水平、动脉粥样硬化予以调控,疗效显著。
Objective To investigate the efficacy of atorvastatin calcium in the treatment of atherosclerotic cerebral infarction and the effect of carotid plaque. Methods Thirty-five patients with atherosclerotic cerebral infarction were enrolled in the study. Clinically,atorvastatin calcium intensive lipid-lowering therapy was given and the study group was set up. Another 35 patients with atherosclerotic cerebral infarction were enrolled in the same time period, and were routinely treated clinically and used as a reference group. The analysis and data comparison were carried out on the clinical treatment and prognosis of the two groups of patients. Results The observation group was superior to the reference group in terms of treatment effect. The numerical value was always more efficient, and the difference from the reference group was larger, P<0.05, which was statistically significant. The observation group was superior to the reference group in terms of blood lipids. The numerical indicators showed a greater improvement in the level of indicators, which was significantly different from the reference group, P<0.05, which was statistically significant. The observation group was superior to the reference group in terms of atherosclerosis, and the carotid plaque area was numerically significant. The improvement of the thickness of the endometrium-middle layer was greater, and it was significantly different from the reference group, P<0.05, which was statistically significant. Conclusion The atorvastatin calcium intensive lipid-lowering therapy for patients with atherosclerotic cerebral infarction has significant curative effect, and it has improved effect on blood lipid level and atherosclerosis.
Objective To investigate the efficacy of atorvastatin calcium in the treatment of atherosclerotic cerebral infarction and the effect of carotid plaque. Methods Thirty-five patients with atherosclerotic cerebral infarction were enrolled in the study. Clinically,atorvastatin calcium intensive lipid-lowering therapy was given and the study group was set up. Another 35 patients with atherosclerotic cerebral infarction were enrolled in the same time period, and were routinely treated clinically and used as a reference group. The analysis and data comparison were carried out on the clinical treatment and prognosis of the two groups of patients. Results The observation group was superior to the reference group in terms of treatment effect. The numerical value was always more efficient, and the difference from the reference group was larger, P<0.05, which was statistically significant. The observation group was superior to the reference group in terms of blood lipids. The numerical indicators showed a greater improvement in the level of indicators, which was significantly different from the reference group, P<0.05, which was statistically significant. The observation group was superior to the reference group in terms of atherosclerosis, and the carotid plaque area was numerically significant. The improvement of the thickness of the endometrium-middle layer was greater, and it was significantly different from the reference group, P<0.05, which was statistically significant. Conclusion The atorvastatin calcium intensive lipid-lowering therapy for patients with atherosclerotic cerebral infarction has significant curative effect, and it has improved effect on blood lipid level and atherosclerosis.
引文
[1]肖东芳.普罗布考联合阿托伐他汀治疗老年脑梗死合并颈动脉粥样硬化斑块患者的疗效及对其脂代谢水平的影响[J].中国民康医学,2017,29(1):8-9.
[2]宗晓芸,邓美珍.急性脑梗死患者颈动脉粥样硬化斑块经阿托伐他汀钙联合氢氯吡格雷治疗的临床观察[J].天津药学,2017,29(6):44-46.
[3]白毅婕,何剑波,苏航.不同剂量阿托伐他汀钙对缺血性脑血管病微出血患者血清炎性因子和血脂水平的影响[J].解放军医药杂志,2018,30(1):82-85.
[4]吴文法,余慧文,邓婉青.应用15mg剂量瑞舒伐他汀对心血管疾病极高风险患者血脂水平及颈动脉斑块的影响和安全性观察[J].中国医药,2018,13(3):341-345.
[5]沈萍.强化降脂对脑梗塞颈动脉粥样斑块厚度的疗效观察[J].现代诊断与治疗,2017,28(7):159-160.
[6]王迪.阿托伐他汀钙片治疗脑梗死患者颈动脉粥样硬化斑块的效果[J]中国当代医药,2017,24(4):64-66.
[7]牟艳春.阿托伐他汀治疗脑梗死患者颈动脉粥样硬化斑块的效果分析[J]中国现代药物应用,2017,11(1):12-14.
[8]徐文锐,汪锦幸,胡勇,等.经颅超声溶栓联合阿托伐他汀钙治疗动脉粥样硬化性脑梗死的临床疗效[J].医学综述,2017,24(1):179-182.
[9]任蓓,张爱香,沙娟娟,等.不同剂量阿托伐他汀钙对脑梗死患者血清炎症因子及颈动脉斑块的影响[J].药物评价研究,2017,40(6):812-815.
[10]周百桂.阿托伐他汀钙对脑梗死患者血流颈动脉斑块的影响分析[J]中国生化药物杂志,2017,42(5):308-310.
[11]沈艳娜.阿托伐他汀钙强化治疗对脑梗死患者血脂及颈动脉粥样硬化的影响[J].慢性病学杂志,2018,20(5):604-605.
[12]宋红英.阿托伐他汀强化降脂治疗对冠心病心绞痛发作情况及血生化指标的影响[J].中国实用医药,2017,12(19):141-142.
[13]莫晓东,唐艺加,龙恩武.阿托伐他汀强化降脂治疗对不稳定型心绞痛患者血脂、炎性细胞因子及心功能的影响[J].解放军医药杂志,2017,29(7):70-73.
[14]衡林,韩坤.急性脑梗死患者应用阿托伐他汀强化降脂治疗对其血脂指标的改善作用[J].世界最新医学信息文摘,2017,17(56):70.
[15]Pan X,Hou R,Ma A,et al.Atorvastatin Upregulates the Expression of miR-126 in Apolipoprotein E-knockout Mice with Carotid Atherosclerotic Plaque.[J].Cellular&Molecular Neurobiology,2017,1(2):1-8.
[16]李姗,邓小容,谭杰,等.阿托伐他汀强化降脂治疗急性脑梗死的疗效及对TNF-α、IL-10、IL-18、MMP-9水平的影响[J].现代生物医学进展,2018,18(11):151-154,190.
[17]Jing G,Zhao P,Liu MX.Effect of atorvastatin calcium on the carotid atherosclerotic plaque and cerebral blood flow indicators in patients with TIA[J].Journal of Hainan Medical University,2017,23(1):61-63.
[18]覃星悦,肖海,农媛.阿托伐他汀强化降脂对急性脑梗死患者血清hsCRP、NSE及MMP-3水平的影响[J].华夏医学,2017,30(5):20-23.
[2]宗晓芸,邓美珍.急性脑梗死患者颈动脉粥样硬化斑块经阿托伐他汀钙联合氢氯吡格雷治疗的临床观察[J].天津药学,2017,29(6):44-46.
[3]白毅婕,何剑波,苏航.不同剂量阿托伐他汀钙对缺血性脑血管病微出血患者血清炎性因子和血脂水平的影响[J].解放军医药杂志,2018,30(1):82-85.
[4]吴文法,余慧文,邓婉青.应用15mg剂量瑞舒伐他汀对心血管疾病极高风险患者血脂水平及颈动脉斑块的影响和安全性观察[J].中国医药,2018,13(3):341-345.
[5]沈萍.强化降脂对脑梗塞颈动脉粥样斑块厚度的疗效观察[J].现代诊断与治疗,2017,28(7):159-160.
[6]王迪.阿托伐他汀钙片治疗脑梗死患者颈动脉粥样硬化斑块的效果[J]中国当代医药,2017,24(4):64-66.
[7]牟艳春.阿托伐他汀治疗脑梗死患者颈动脉粥样硬化斑块的效果分析[J]中国现代药物应用,2017,11(1):12-14.
[8]徐文锐,汪锦幸,胡勇,等.经颅超声溶栓联合阿托伐他汀钙治疗动脉粥样硬化性脑梗死的临床疗效[J].医学综述,2017,24(1):179-182.
[9]任蓓,张爱香,沙娟娟,等.不同剂量阿托伐他汀钙对脑梗死患者血清炎症因子及颈动脉斑块的影响[J].药物评价研究,2017,40(6):812-815.
[10]周百桂.阿托伐他汀钙对脑梗死患者血流颈动脉斑块的影响分析[J]中国生化药物杂志,2017,42(5):308-310.
[11]沈艳娜.阿托伐他汀钙强化治疗对脑梗死患者血脂及颈动脉粥样硬化的影响[J].慢性病学杂志,2018,20(5):604-605.
[12]宋红英.阿托伐他汀强化降脂治疗对冠心病心绞痛发作情况及血生化指标的影响[J].中国实用医药,2017,12(19):141-142.
[13]莫晓东,唐艺加,龙恩武.阿托伐他汀强化降脂治疗对不稳定型心绞痛患者血脂、炎性细胞因子及心功能的影响[J].解放军医药杂志,2017,29(7):70-73.
[14]衡林,韩坤.急性脑梗死患者应用阿托伐他汀强化降脂治疗对其血脂指标的改善作用[J].世界最新医学信息文摘,2017,17(56):70.
[15]Pan X,Hou R,Ma A,et al.Atorvastatin Upregulates the Expression of miR-126 in Apolipoprotein E-knockout Mice with Carotid Atherosclerotic Plaque.[J].Cellular&Molecular Neurobiology,2017,1(2):1-8.
[16]李姗,邓小容,谭杰,等.阿托伐他汀强化降脂治疗急性脑梗死的疗效及对TNF-α、IL-10、IL-18、MMP-9水平的影响[J].现代生物医学进展,2018,18(11):151-154,190.
[17]Jing G,Zhao P,Liu MX.Effect of atorvastatin calcium on the carotid atherosclerotic plaque and cerebral blood flow indicators in patients with TIA[J].Journal of Hainan Medical University,2017,23(1):61-63.
[18]覃星悦,肖海,农媛.阿托伐他汀强化降脂对急性脑梗死患者血清hsCRP、NSE及MMP-3水平的影响[J].华夏医学,2017,30(5):20-23.